EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y

Core Insights - Editas Medicine reported a narrower loss of 6 cents per share in Q4 2025, compared to a loss of 55 cents per share in the same quarter last year, and better than the Zacks Consensus Estimate of a loss of 27 cents [1][7] - The company's collaboration and R&D revenues were $24.7 million in Q4 2025, down 19% year-over-year, but significantly exceeded the Zacks Consensus Estimate of $7 million [2][7] - Editas shares increased by 16% following the announcement of better-than-expected Q4 results [3] Financial Performance - R&D expenses decreased by 44% to $27.4 million in Q4 2025 from $48.6 million in the previous year, primarily due to lower clinical and manufacturing costs after the abandonment of the reni-cel program [4] - General and administrative expenses fell by 31% year-over-year to $11.4 million, attributed to reduced workforce and professional service expenses [5] - Restructuring and impairment charges improved by $18.5 million, resulting in a benefit of $6.3 million in Q4 2025 compared to a charge of $12.2 million a year earlier [6] Annual Overview - For the full year 2025, Editas recorded total revenues of $40.5 million, surpassing the Zacks Consensus Estimate of $21.4 million, and representing a 25% increase from $32.3 million in 2024 [10] - The loss per share for 2025 was $1.80, which was better than the Zacks Consensus Estimate of a loss of $2.03 per share, and an improvement from a loss of $2.88 per share in 2024 [10] Pipeline Development - Editas currently has no approved products and is focusing on pipeline development, having discontinued the reni-cel program in late 2024 due to the lack of a commercial partner [11] - The company has nominated EDIT-401 as its lead in vivo development candidate, aimed at significantly reducing LDL cholesterol levels, with promising preclinical results showing over 90% LDL-C reductions [12][13] - Editas plans to file an investigational new drug application by mid-2026 and initiate a first-in-human study of EDIT-401 later this year, with initial proof-of-concept data expected by the end of 2026 [14] Cash Position - As of December 31, 2025, Editas had cash, cash equivalents, and investments totaling $146.6 million, down from $165.6 million as of September 30, 2025, with expectations to fund operations into Q3 2027 [9]